GERD in Children with Medical Complexity

Definitions:

GER	Passage of gastric contents into the esophagus with or without regurgitation/vomiting
GERD	When GER leads to troublesome symptoms and/or complications
Refractory GERD	GERD not responding to optimal treatment after 8 weeks
Optimal Therapy	Maximum pharmacologic and/or nonpharmacologic therapy based on the region of practice of the subspecialist
Regurgitation	Passage of refluxed contents into the pharynx, mouth or from the mouth; "spitting-up" = regurgitation
Vomiting	Forceful expulsion of gastric contents through the mouth

Clinical features/complications:

Symptoms	Signs	
General	General	
Discomfort/irritability*	Dental erosion	
Failure to Thrive	Anemia	
Feeding refusal		
Dystonic neck posturing (Sandifer syndrome)		
Gastrointestinal	Gastrointestinal	
Recurrent regurgitation with/	Esophagitis	
without vomiting in the older child	Esophageal stricture	
Heartburn/chest pain [†]	Barrett esophagus	
Epigastric pain [†]	1 0	
Hematemesis		
Dysphagia/odynophagia		
Airway	Airway	
Wheezing	Apnea spells	
Stridor	Asthma	
Cough	Recurrent pneumonia	
Hoarseness	associated with aspiration	
	Recurrent otitis media	

 $BRUE = brief \ resolved \ unexplained \ event; \ GERD = gastroesophageal$ reflux disease.

*If excessive irritability and pain is the single manifestation, it is unlikely to be related to GERD. [†]Typical symptoms of GERD in older children.

Others:

- Sialorrhea -
- Mouth malodor

Red flags that suggest disorders other than GERD:

Symptoms and signs	Remarks	
General		
Weight loss	Suggesting a variety of conditions, including systemic infections	
Lethargy		
Fever		
Excessive irritability/pain		
Dysuria	May suggest urinary tract infection, especially in infants and young children	
Onset of regurgitation/vomiting >6 months or increasing/persisting >12-18 months of age	Late onset as well as symptoms increasing or persisting after infancy, based on natural course of the disease, may indicate a diagnosis other than GERD	
Neurological		
Bulging fontanel/rapidly increasing	May suggest raised intracranial pressure for example due to meningitis, brain tumor or	
head circumference	hydrocephalus	
Seizures		
Macro/microcephaly		
Gastrointestinal		
Persistent forceful vomiting	Indicative of hypertrophic pyloric stenosis (infants up to 2 months old)	
Nocturnal vomiting	May suggest increased intracranial pressure	
Bilious vomiting	Regarded as symptom of intestinal obstruction. Possible causes include Hirschsprung disease, intestinal atresia or mid-gut volvulus or intussusception	
Hematemesis	Suggests a potentially serious bleed from the esophagus, stomach or upper gut, possibly GERD- associated, occurring from acid-peptic disease [*] , Mallory-Weiss tear [†] or reflux-esophagitis.	
Chronic diarrhea	May suggest food protein-induced gastroenteropathy [‡]	
Rectal bleeding	Indicative of multiple conditions, including bacterial gastroenteritis, inflammatory bowel disease, as well as acute surgical conditions and food protein-induced gastroenteropathy rectal bleeding ⁴ (bleeding caused by proctocolitis)	
Abdominal distension	Indicative of obstruction, dysmotility, or anatomic abnormalities	

GERD = gastroesophageal reflux disease; NSAID = non-steroidal antiinflammatory drugs. *Especially with NSAID use. †Associated with vomiting. ‡More likely in infants with eczema and/or a strong family history of atopic disease.

Differential diagnosis of GERD:

Gastrointestinal obstruction	Other gastrointestinal disorders
Pyloric stenosis	Achalasia
Malrotation with volvulus	Gastroparesis
Intussusception	Gastroenteritis
Hirschsprung disease	Peptic ulcer
Antral/duodenal web	Eosinophilic esophagitis
Foreign body	Food allergy/intolerance
Incarcerated hernia	Inflammatory bowel disease
Superior mesenteric artery (SMA) syndrome	Pancreatitis
	Appendicitis
Neurologic	Infectious
Hydrocephalus	Sepsis/meningitis
Subdural hematoma	Urinary tract infection
Intracranial hemorrhage	Upper/lower airway infection
Intracranial mass	Otitis media
	Hepatitis
Metabolic/endocrine	Others
Galactosemia	Pediatric condition falsification (PCF)/factitious disorder by proxy (FDP)
Hereditary fructose intolerance	Child neglect or abuse
Urea cycle defects	Self-induced vomiting
Amino and organic acidemias	Cyclic vomiting syndrome
Fatty acid oxidation disorders	Rumination syndrome
Metabolic acidosis	
Congenital adrenal hyperplasia/adrenal crisis	
Toxic	Renal
Lead poisoning	Obstructive uropathy
Other toxins	Renal insufficiency
Cardiac	
Heart failure	
Vascular ring	
Autonomic dysfunction	

ESPGHAN = European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; GERD = gastroesophageal reflux disease; NASPGHAN = North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *Adapted from the ESPGHAN/NASPGHAN 2009 GERD guidelines.

Investigations:

U/A	NOT to diagnose GERD but to exclude anatomical abnormalities	
Contrast studies	NOT to diagnose GERD but to exclude anatomical abnormalities	
Upper GI scope	To (1) assess complications of GERD, (2) R/O an underlying mucosal disease and (3)	
with biopsies	prior to escalation of therapy	
Manometry	NOT to diagnose GERD but used when a motility disorder is suspected	
4-8 week trial of	- NOT used as a diagnostic test for GERD in infants (unless a referral is not possible)	
PPIs	- Diagnostic test for GERD in children with typical esophageal symptoms	
2-4 week trial of	- After optimal non-pharmacological treatment fails in infants	
extensively	- To diagnose Cow's Milk Protein Allergy (CMPA) in infants (may present like GERD)	
hydrolyzed (or AA-		
based) formula		
Gastric pH	- Often checked before administration of acid suppressant	
	- To determine the efficacy of acid suppression therapy (poor evidence)	
	- Target pH >4	
pH-metry (when	To (1) correlate persistent troublesome symptoms with acid gastroesophageal reflux	
pH-MII is not	events, (2) clarify the role of acid reflux in the etiology of esophagitis and other signs	
available)	and symptoms of GERD and (3) determine the efficacy of acid suppression therapy	
pH-MII	To (1) correlate persistent troublesome symptoms with acid and non-acid	
	gastroesophageal reflux events, (2) clarify the role of acid and non-acid reflux in the	
	etiology of esophagitis and other signs and symptoms of GERD, (3) determine the	
	efficacy of acid suppression therapy, and (4) differentiate NERD, hypersensitive	
	esophagus, and functional heartburn in patients with normal endoscopy	
Non-erosive reflux	Esophageal symptoms with lack of evidence of reflux on endoscopy but do have an	
disease (NERD)	abnormal acid burden that may or may not trigger symptoms	
Reflux	Esophageal symptoms (i.e., heartburn or chest pain) with lack of evidence of reflux on	
hypersensitivity	endoscopy or abnormal acid burden on reflux monitoring + evidence that symptoms are	

triggered by reflux eventsFunctional heartburnReflux hypersensitivity with NO evidence that symptoms are triggered by reflux events

Non-pharmacological treatment:

- Infants:
 - Thickened feedings for treating regurgitation/vomiting
 - Modifying feeding volumes and frequency to avoid overfeeding
 - o Head elevation or left lateral positioning in non-sleeping infants
 - Continuing breastfeeding
 - o Extensively hydrolyzed (or AA-based) formula if A/W Cow's Milk Protein Allergy.
- Children:
 - Head elevation or left lateral positioning in non-sleeping children
 - Weight control

Other insights:

- > NG feeding may exacerbate reflux
- > No evidence to support massage therapy, prebiotics, probiotics or herbs

Pharmacological treatment:

1. Acid suppressants (PPI & H2RA)

- Benefits:
 - > Decrease reflux index (% of time when esophageal pH <4)
 - > Decrease irritation and damage to esophageal mucosa
 - > Decrease symptomatic reflux (i.e., pain/irritability)
 - > Promote healing of existing esophageal damage
- Age & acid suppressants:
 - Children < 1 Y/O:</p>
 - May not improve non-specific GERD symptoms (e.g., irritability, vomiting)
 - Can consider for endoscopy-proved esophagitis
 - > Children > 1 Y/O:
 - Provide symptomatic relive and promote healing of reflux esophagitis
 - Greater evidence of benefit for PPI than H2RA
 - Other insights:
 - ▶ PPI are BETTER then H2RA \rightarrow longer effective duration and NO tachyphylaxis
 - > No PPI superior to others; no H2RA superior to others
 - > Do not improve asthma symptoms in GERD patients
 - > No evidence that combined PPI & H2RA is better than monotherapy
 - > Lack of improvement should trigger re-evaluation for alternate diagnosis

	PPT	H2RB
Examples	 Omeprazole, pantoprazole, esomeprazole, rabeprazole, lansoprazole Omeprazole: Tablet can be pealed for enteral tube administration; liquid has a bitter taste and can be used for enteral tube administration Pantoprazole: IV preparation available; tablets are enteric coated – do not crush tablets or administer tablets via gastric tubes; no liquid preparations available Esomeprazole: Sachet that can used for enteral tube administration Rabeprazole: Considered for extensive CYP2C19 metabolizers Lansoprazole: ODT is ideal for PO feeding children; can be split and dissolved in water but may block enteral tubes, capsules can be opened and mixed with food/juice, evidence for liquid's stability/potency not well established 	Ranitidine, famotidine, cimetidine, nizatidine

De sin a		Defended the former dame (former tiding)
Dosing	Refer to the formulary (omeprazole, lansoprazole,	Refer to the formulary (famotidine)
МоА	pantoprazole)	Deversible inhibition of betamine 2
МОА	Reduces meal-induced acid secretion by inhibition of	Reversible inhibition of hetamine-2
	Na/K ATPase (proton pump) on gastric parietal cells (may be reversable inhibition and need more	receptors on gastric parietal cells
		(reduce basal acid secretion by 70%)
Metabolism	frequent dosing if effect wears off) - Metabolism by CYP2C19	- By CYP P450 enzymes
Metabolism	- If inadequate response, consider	- Cimetidine is a weak/moderate
	pharmacogenetics due to 2C19 polymorphisms	inhibitor of CYP P450 enzymes
	(need higher dose or switch to rabeprazole as it	minibitor of CTP P450 enzymes
	less metabolized by 2C19)	
	- Can use genetic testing to identify rate of 2C19	
	metabolism	
Timing	- Onset 1-2 hr, peak 2 hr, duration 24-72 hr	Onset 30 min, peak 2.5 hr,
	- Max acid suppression can take 4-7 days (can	duration 6 hr (4-10 hr)
	use H2RA as a bridge)	
	- Most guidelines recommended 4–8 week trial	
Side-effects	- Idiosyncratic reactions (2-7%; up to 14%):	Headache (17%; up to 70%),
	Headache, nausea, diarrhea, constipation	fatigue/somnolence, dizziness, risk
	- Drug-drug interaction: CYP2C19 & CYP3A4 (e.g.,	of pneumonia (causal relationship
	omeprazole-clobazam interaction)	not established), A/W NEC in very
	- Drug-induced hypergastrinemia (gastric parietal	low BW infants
	cell hyperplasia and occasionally fundic gland	
	polyps)	
	- Drug-induced hypochlorhydria: May increase risk	
	for pneumonia and GE, as well as candidemia	
	and NEC in very low BW infants	
	- Increased risk of C. difficile, SIBO, nephritis and	
	poor bone health (causing fractures)	
	Use LOWEST effective dose and duration	
	to minimize side-effects	
Goal gastric pH	>4	>4
Other insights	- Acid-labile: Ideally given 30-60 min before feeds	 Tachyphylaxis: Rapid decline in
	(bioavailability decreases by 50-70% if given 30	efficacy if used >6 weeks
	min after feeds); delayed-release preparations	(increasing the dose does not
	prevent drug degradation by acid	overcome it)
	- Concerns about rebound acid hypersecretion	
	with sudden discontinuation	
	- No PPI approved for use in children <1 Y/O	
	(except for endoscopically documented acid-	
	induced condition like erosive esophagitis)	
	 Approved for > 1 Y/O: Omeprazole, 	
	esomeprazole, lansoprazole	
	 Approved for > 12 Y/O: Rabeprazole 	

2. Prokinetic agents

.

- Benefits:
 - Increase LES pressure
 - Increase rate of gastric emptying
 - Increase esophageal and intestinal peristalsis
 - Decrease regurgitation/vomiting
- Other insights:
 - > Insufficient evidence to justify routine use in children with GERD
 - > Second line, add-on treatment if acid suppressants failed to control GERD
 - symptoms/complications, in patients with delayed gastric emptying
 - > Often trialed before considering surgical interventions
 - Significant safety concerns with limited data on efficacy in literature (weigh risks and benefits for each patient)
- Examples: Domperidone, metoclopramide, cisapride

Domperidone	- Antagonist of peripheral dopamine D2 receptors
-	- Dosing: Refer to the formulary
	- Does not cross BBB (does not cause extrapyramidal symptoms, unlike metoclopramide)
	- Peaks at 30 min (given 30 min before feeds)
	- Metabolized by CYP3A4; potential for drug interactions
	- Half-life prolonged in severe renal impairment
	- Side-effects: QTc prolongation (refer to the document on prokinetic agents & QTc
	prolongation), others including headache, dry mouth, diarrhea (dose-dependent)

3. Others:


Baclofen prior to surgery in children in whom other pharmacological treatments have failed
 Antiacids, alginates and sucralfate are NOT RECOMMENDED for long-term use in children

Surgical treatment:


- Indications:
 - 1) Symptoms/complications refractory to optimal therapy after appropriate evaluation to exclude other underlying diseases
 - Chronic conditions (e.g., neurologically impaired) with a significant risk of GERD-related complications
 - 3) Need for chronic pharmacotherapy for control of signs and/or symptoms of GERD
- Surgical interventions:
 - Fundoplication
 - Post-pyloric feeding (GJ or surgical J-tube)
 - Consider continuous GT feeding as a bridge

Referral to gastroenterologist indications:

- > Alarm signs or symptoms
- > No response to 4 to 8 weeks of optimal therapy for GERD
- > Failure to permanently wean from pharmacological treatment within 6 to 12 months



Algorithm 1: Management of GERD in infants



Algorithm 2: Management of GERD in children